{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T10:15:07Z","timestamp":1756635307241,"version":"3.40.5"},"reference-count":45,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title><jats:sec id=\"S0317167122000439_as1\"><jats:title>Background:<\/jats:title><jats:p>PREDICT was a Canadian, multicenter, prospective, observational study in adults na\u00efve to onabotulinumtoxinA treatment for chronic migraine (CM). We descriptively assess health resource utilization, work productivity, and acute medication use.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167122000439_as2\"><jats:title>Methods:<\/jats:title><jats:p>OnabotulinumtoxinA (155\u2013195 U) was administered every 12 weeks over 2 years (\u22647 treatment cycles). Participants completed a 4-item health resource utilization questionnaire and 6-item Work Productivity and Activity Impairment Questionnaire: Specific Health Problem V2.0. Acute medication use was recorded in daily headache diaries. Treatment-emergent adverse events were recorded throughout the study.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167122000439_as3\"><jats:title>Results:<\/jats:title><jats:p>A total of 197 participants were enrolled, and 184 received \u22651 treatment with onabotulinumtoxinA and were included in the analysis. Between baseline and the final visit, there were decreases in the percentage of participants who reported headache-related healthcare professional visit(s) (96.2% to 76.8%) and those who received headache-related diagnostic testing (37.5% to 9.9%). Reductions from baseline were also observed in the mean number of headache-related visits to an emergency room\/urgent care clinic (2.5 to 1.4) and median headache-related hospital admissions (4.0 to 1.0). OnabotulinumtoxinA improved work productivity and reduced the mean (standard deviation) number of hours missed from work over a 7-day period (6.1 [9.7] to 3.0 [6.8]). Mean (standard deviation) acute medication use decreased from baseline (15.2 [7.6] to 9.1 [6.5] days). No new safety signals were identified.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167122000439_as4\"><jats:title>Conclusions:<\/jats:title><jats:p>Real-world evidence from PREDICT demonstrates that onabotulinumtoxinA treatment for CM in the Canadian population reduces health resource utilization and acute medication use and improves workplace productivity, supporting the long-term benefits of using onabotulinumtoxinA for CM.<\/jats:p><\/jats:sec>","DOI":"10.1017\/cjn.2022.43","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T10:40:32Z","timestamp":1650883232000},"page":"418-427","source":"Crossref","is-referenced-by-count":1,"title":["OnabotulinumtoxinA Reduces Health Resource Utilization in Chronic Migraine: PREDICT Study"],"prefix":"10.1017","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1696-1629","authenticated-orcid":false,"given":"Werner J.","family":"Becker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Boudreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Finkelstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrie","family":"Graboski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Christie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meetu","family":"Bhogal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goran","family":"Davidovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"S0317167122000439_ref35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01766.x"},{"key":"S0317167122000439_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.05.003"},{"key":"S0317167122000439_ref9","doi-asserted-by":"publisher","DOI":"10.1111\/head.13613"},{"key":"S0317167122000439_ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00990.x"},{"key":"S0317167122000439_ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1386-8"},{"key":"S0317167122000439_ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0894-6"},{"key":"S0317167122000439_ref34","first-page":"1","article-title":"OnabotulinumtoxinA improves quality of life in chronic migraine: the PREDICT study","author":"Boudreau","year":"2021","journal-title":"Can J Neurol Sci."},{"key":"S0317167122000439_ref43","doi-asserted-by":"publisher","DOI":"10.33425\/2639-846X.1037"},{"key":"S0317167122000439_ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1030-z"},{"key":"S0317167122000439_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.02.013"},{"key":"S0317167122000439_ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0840-8"},{"key":"S0317167122000439_ref29","doi-asserted-by":"publisher","DOI":"10.1111\/head.12456"},{"key":"S0317167122000439_ref32","doi-asserted-by":"crossref","first-page":"S38.007","DOI":"10.1212\/WNL.92.15_supplement.S38.007","article-title":"Reduction in healthcare resource utilization in patients treated with onabotulinumtoxinA for chronic migraine: results from the REPOSE study","volume":"92","author":"Kollewe","year":"2019","journal-title":"Neurology."},{"key":"S0317167122000439_ref36","doi-asserted-by":"publisher","DOI":"10.1111\/head.13074"},{"key":"S0317167122000439_ref42","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.124"},{"key":"S0317167122000439_ref45","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-016-0591-3"},{"key":"S0317167122000439_ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0976-1"},{"key":"S0317167122000439_ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01678.x"},{"key":"S0317167122000439_ref31","doi-asserted-by":"publisher","DOI":"10.1177\/0333102415621294"},{"key":"S0317167122000439_ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-013-0385-0"},{"key":"S0317167122000439_ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0802-6"},{"key":"S0317167122000439_ref37","unstructured":"37. Botox [product monograph]. Markham, ON: Allergan, Inc.; 2014."},{"key":"S0317167122000439_ref3","first-page":"10","article-title":"Prevalence of migraine in the Canadian household population","volume":"25","author":"Ramage-Morin","year":"2014","journal-title":"Health Rep."},{"key":"S0317167122000439_ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1636-9"},{"key":"S0317167122000439_ref28","doi-asserted-by":"publisher","DOI":"10.1177\/2150132720959936"},{"key":"S0317167122000439_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.06.001"},{"key":"S0317167122000439_ref2","first-page":"1","article-title":"The international classification of headache disorders","volume":"38","year":"2018","journal-title":"Cephalalgia."},{"key":"S0317167122000439_ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-011-0233-z"},{"key":"S0317167122000439_ref17","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0b013e3181c1dc56"},{"key":"S0317167122000439_ref7","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410381145"},{"key":"S0317167122000439_ref33","first-page":"108","article-title":"Healthcare resource utilization in adult patients treated with onabotulinumtoxinA for chronic migraine: results from the COMPEL study","volume":"59","author":"Rothrock","year":"2019","journal-title":"Headache."},{"key":"S0317167122000439_ref41","first-page":"6","article-title":"A multicenter, prospective, randomized, open-label study to compare onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine: patient reported functional outcomes from the FORWARD study","volume":"38","author":"Blumenfeld","year":"2018","journal-title":"Cephalalgia."},{"key":"S0317167122000439_ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01941.x"},{"key":"S0317167122000439_ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01945.x"},{"key":"S0317167122000439_ref38","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"S0317167122000439_ref8","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411398400"},{"key":"S0317167122000439_ref12","doi-asserted-by":"publisher","DOI":"10.1111\/head.12755"},{"key":"S0317167122000439_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15440-8"},{"key":"S0317167122000439_ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2212"},{"key":"S0317167122000439_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-62627-1.00025-1"},{"key":"S0317167122000439_ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01990.x"},{"key":"S0317167122000439_ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2005.01077.x"},{"key":"S0317167122000439_ref39","doi-asserted-by":"publisher","DOI":"10.1207\/s15327752jpa6703_13"},{"key":"S0317167122000439_ref40","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"S0317167122000439_ref1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13300"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167122000439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T22:16:51Z","timestamp":1727043411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167122000439\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0317167122000439"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2022.43","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"type":"print","value":"0317-1671"},{"type":"electronic","value":"2057-0155"}],"subject":[],"published":{"date-parts":[[2022,4,25]]}}}